5-Amino-1MQ

5-Amino-1MQ (5-Amino-1-Methylquinolinium): A Scientific Review

Based on peer-reviewed literature — see References. Last updated: April 2026.

The Short Version

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT) — a cytosolic methyltransferase linking nicotinamide (vitamin B3) metabolism to the broader methionine cycle and NAD♠ salvage pathway. It was first characterised as an NNMT inhibitor by Neelakantan, Watowich, and colleagues at the University of Texas Medical Branch in 2017 and 2018.

The compound appears in this series because it is routinely discussed alongside peptides in the wellness and metabolic optimisation community and represents a genuinely novel mechanism of action for metabolic disease. Where GLP-1 agonists reduce energy intake, 5-amino-1MQ — at least in animal models — appears to increase energy expenditure without altering food intake. That is a mechanistically distinct and scientifically interesting phenotype. The preclinical evidence is substantive: NNMT knockdown and 5-amino-1MQ treatment in diet-induced obese mice reduce body weight, white adipose mass, adipocyte size, and plasma cholesterol; improve insulin sensitivity; and do not alter food intake. More recent work (2024) shows additive benefits over exercise in aged mice for grip strength and endurance.

The honest statement that follows: there are no published human clinical trials, no human pharmacokinetic data, no human safety data, and no regulatory approval anywhere in the world. Clinics administering 5-amino-1MQ to humans are doing so without any of the safety information that normally precedes first-in-human use. The preclinical profile is genuinely promising; the clinical situation is genuinely unknown.

What Is NNMT and Why Does It Matter?

NNMT’s enzymatic reaction

NNMT (nicotinamide N-methyltransferase) catalyses the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (MNA) and S-adenosyl-homocysteine (SAH). This looks like a simple detoxification reaction, but NNMT’s metabolic significance extends far beyond detoxification through two critical connections.^[3]

Connection 1 — NAD♠ salvage pathway: Nicotinamide is a key precursor in the NAD♠ salvage pathway (NAM → NAMPT → NMN → NAD♠). When NNMT methylates NAM to MNA, it diverts NAM away from NAD♠ synthesis. Elevated NNMT activity therefore reduces NAD♠ availability — impairing sirtuin (SIRT1, SIRT3) activity, PARP, and the mitochondrial electron transport chain.

Connection 2 — Methionine cycle / SAM depletion: SAM is the universal methyl donor for hundreds of methylation reactions (DNA, histones, RNA capping, metabolites). When NNMT consumes large amounts of SAM, it depletes the methyl donor pool. SAH also directly inhibits most SAM-dependent methyltransferases. High NNMT activity therefore creates a dual drain: depleting both NAD♠ and SAM simultaneously.

NNMT expression patterns: where it matters

NNMT is expressed in liver, kidney, lung, brain, heart, and skeletal muscle — but critically, it is highly expressed in white adipose tissue (WAT) and dramatically upregulated in the WAT of obese and diabetic animals and humans. Plasma levels of the NNMT reaction product 1-methylnicotinamide (1-MNA) correlate with adipose NNMT expression, individuals’ BMI, and waist circumference, suggesting the target to be clinically relevant.^[4] In obesity, elevated WAT NNMT → more NAM converted to MNA → less NAD♠ in adipocytes → reduced sirtuin activity → impaired fatty acid oxidation → adipocytes locked in a fat-storing, metabolically hypoactive state. High NNMT creates a self-reinforcing cycle of adipose metabolic dysfunction.

The Discovery of 5-Amino-1MQ

Most NNMT inhibitors developed before 2017 were charged bisubstrate analogues — large, polar molecules that could not cross cell membranes and therefore could not reach the cytosolic NNMT enzyme. The Watowich group at UTMB systematically explored 1-methylquinolinium (1MQ) scaffold analogues with amine substitutions at different positions, balancing membrane permeability and NNMT binding via PAMPA and Caco-2 bidirectional transport assays.

5-Amino-1MQ emerged as the lead compound: an amine at the 5-position produced high passive membrane permeability, high active bidirectional transport (favourable oral absorption), potent competitive NNMT inhibition, and crucially — high selectivity. 5-amino-1MQ does not inhibit related SAM-dependent methyltransferases or enzymes in NAD♠ salvage pathways. This selectivity profile is critical: an NNMT inhibitor that also disrupted DNMT or HMT enzymes would have serious genotoxic and epigenetic concerns.^[1]

Mechanism of Action: From NNMT Inhibition to Metabolic Reprogramming

When 5-amino-1MQ inhibits NNMT in white adipocytes: ↓ MNA (less NAM methylated; measurable surrogate for NNMT inhibition); ↑ NAD♠ (less NAM diverted from the salvage pathway); and ↑ SAM (less consumed by NNMT; restored cellular methylation capacity).

With restored NAD♠: SIRT1 activation deacetylates PGC-1α (promoting mitochondrial biogenesis and fatty acid oxidation) and FOXO1 (improving insulin sensitivity); SIRT3 activation activates fatty acid oxidation enzymes (LCAD, VLCAD) and antioxidant enzymes (MnSOD); AMPK activation inhibits lipogenesis (ACC, FASN) and promotes fatty acid oxidation; and the combined SIRT1-AMPK-PGC-1α axis promotes new mitochondria formation in adipocytes. The net result: adipocytes shift toward increased fatty acid oxidation, reduced lipogenesis, and decreased fat accumulation.

Additionally, 5-amino-1MQ increases GLUT4 transporter expression, improving glucose clearance from blood and reducing glucose-to-fat conversion — improving insulin sensitivity independently of body weight reduction.^[4]

Preclinical Evidence: What the Animal Data Shows

Key 2017/2018 studies (Neelakantan, Watowich et al.)

In vitro (3T3-L1 adipocytes): NNMT protein expression was found to be ~37-fold higher in adipocytes vs. pre-adipocytes. 5-amino-1MQ (30 μM) in both pre-adipocytes and adipocytes resulted in significant reduction in intracellular 1-MNA, increased intracellular NAD♠ and SAM, and suppressed lipogenesis in adipocytes.^[1]

In vivo (diet-induced obese mice; 11 days SC injection at ~34 mg/kg/day): 5-amino-1MQ-treated mice had significantly reduced body weights, white adipose masses, and adipocyte sizes. Notably, 5-amino-1MQ treatment did not show a significant impact on food intake and showed no observable adverse effects. Key quantitative results: ~35% reduction in epididymal WAT mass and adipocyte size; significant reduction in plasma total cholesterol; no change in food intake.^[2] This “weight loss without appetite suppression” phenotype is mechanistically distinct from all GLP-1-based therapies.

2021 study (Sampson et al.)

NNMT inhibition combined with low-fat diet promoted dramatic whole-body adiposity and weight loss in diet-induced obese mice, rapidly normalising these measures to levels statistically indistinguishable from lean control mice — suggesting additive benefit when combined with dietary intervention.^[7]

2024 muscle/exercise study (Dimet-Wiley, Watowich et al.; Scientific Reports)

Mechanistic basis: NNMT inhibition → ↑NAD♠ in muscle → SIRT1/SIRT3 activation → improved mitochondrial function → reduced muscle fatigue and faster recovery. In aged mice, satellite cell (muscle stem cell) activation was also observed, with treated mice showing 2-fold larger myofibre size and 70% stronger contractile force in healed muscle — positioning NNMT inhibition as a potential approach for age-related sarcopenia, a condition with no currently approved pharmacological treatment.

The NNMT Target in Broader Disease

Cancer: NNMT is overexpressed in multiple cancer types (thyroid, bladder, kidney, colorectal, gastric, lung, and others), associated with altered energy metabolism, drug resistance, enhanced invasiveness, and epigenetic silencing of tumour suppressors via SAM depletion. In cancer cell lines, NNMT inhibition reduces proliferation and restores drug sensitivity. However, the cancer biology of NNMT is complex: 1-MNA (the product NNMT generates) has been proposed to have independent anti-inflammatory and vasoprotective effects, and reducing MNA by inhibiting NNMT might not be uniformly beneficial. The cancer biology remains an active research area where simplistic conclusions are unwarranted.

Cardiovascular disease: NNMT-mediated NAD♠ depletion impairs mitochondrial function, sirtuin activity, redox balance, and energy metabolism, creating a pro-atherogenic environment. NNMT upregulation also elevates homocysteine: SAH (produced when NNMT consumes SAM) can be hydrolysed to homocysteine — a well-established cardiovascular risk factor via endothelial damage and thrombosis promotion.^[5] Fibrosis: NNMT is upregulated in fibrotic tissues (hepatic, renal, cardiac); high NNMT → depleted SAM → impaired methylation → epigenetic dysregulation promoting fibroblast activation. NNMT inhibition has shown anti-fibrotic effects in liver and kidney fibrosis models.

What 5-Amino-1MQ Is Not

Not a peptide: 5-amino-1MQ is a small-molecule quinolinium salt (MW ~159 Da free cation; ~286 Da iodide salt) with no peptide bonds and no amino acid sequence. The frequent description of it as a “peptide” in wellness contexts is incorrect. Not interchangeable with NMN or NR: NMN and NR directly supplement NAD♠ precursors; 5-amino-1MQ inhibits the enzyme that diverts NAM away from NAD♠ synthesis — a different point of intervention. These approaches may be complementary rather than substitutable. The safety profile of NAD♠ precursors does not extend to NNMT inhibitors by any logical transference.

Oral Bioavailability: A Practical Advantage

Unlike most peptides covered in this series, 5-amino-1MQ is a small, stable, membrane-permeable molecule that survives oral administration and achieves meaningful systemic exposure. The Caco-2 bidirectional transport data from the 2017 characterisation study confirmed active transport-mediated absorption — a significant practical advantage: oral dosing, stable at room temperature, no reconstitution, no injection. The most widely cited community dosing is 50–150 mg daily orally, based on allometric scaling from mouse doses, but this calculation has not been validated in human pharmacokinetic studies.

Regulatory Status

Multiple wellness clinics and online supplement vendors are selling 5-amino-1MQ for human consumption despite this regulatory classification. The questions that standard drug development answers — maximum tolerated dose, human half-life, metabolites produced, tissue accumulation, drug interactions — are entirely unanswered for this compound. The absence of observable adverse effects in rodents over 11-day treatment periods is reassuring but profoundly insufficient to establish human safety, particularly for long-term use.

Common Misconceptions

“5-amino-1MQ is a peptide.”

It is not. It is a small quaternary ammonium molecule with no peptide bonds. The confusion arises from its appearance in peptide research communities and clinic “peptide programmes.”

“Human trials have confirmed it works.”

No human clinical trials have been published or registered. Community anecdotes and clinic reports are not clinical trials.

“Since NAD♠ boosting is safe (NMN, NR), 5-amino-1MQ is also safe.”

NMN and NR supplement NAD♠ precursors directly. 5-amino-1MQ inhibits an enzyme with roles in methylation, detoxification, and complex tumour biology. These are mechanistically distinct interventions with different risk profiles. The safety of NAD♠ precursors does not extend to NNMT inhibitors.

Key Takeaways

1. ✅ 5-Amino-1MQ is a mechanistically novel NNMT inhibitor with a compelling preclinical profile. The target is well-validated as a metabolic regulator; the compound is potent, selective, membrane-permeable, and orally bioavailable — genuine drug-development advantages.^[1]
2. ✅ The preclinical evidence is substantive and mechanistically coherent. Diet-induced obese mice show significant body weight and adipose mass reduction, improved insulin sensitivity, and reduced cholesterol — without changes in food intake. This “energy expenditure without appetite suppression” phenotype is mechanistically distinct from all approved obesity pharmacotherapy.^[2]
3. The 2024 muscle data is the most recent and clinically interesting preclinical finding. NNMT inhibition improved grip strength more than exercise alone in aged mice and sustained running endurance, with satellite cell activation providing mechanistic relevance to sarcopenia.^[6]
4. ⚠️ No human data exists. No pharmacokinetics, no safety, no efficacy. The complete absence of any human trial data means the jump from promising rodent results to human use is unsupported — not a minor regulatory technicality, but a genuine unknown regarding human safety.
5. ⚠️ The regulatory status is clear. FDA has classified 5-amino-1MQ as an unapproved new drug. Human administration outside a registered trial is a federal regulatory violation. Clinics administering it are doing so without the safety foundation that informed consent requires.

References